Endowed Chair Research Articles

Passions, Pandemic, and Public Policy

[...]we have a body of laws that tell people what they can and cannot do—such as wearing seatbelts, driving while intoxicated, or stopping at a red light, just to name a few examples. [...]as the recently passed abortion law in Texas and anti-voting laws that disproportionately affect people of color have shown, white men want to retain their power to control women's bodies and disenfranchise people of color. 10.1177/15248399211016463 PMID: 33966471 Andrew A. Nierenberg, MD, holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at MGH, and is the Director of the Dauten Family Center for Bipolar Treatment Innovation, and the Director, Center for Clinical Research Education, MGH Research Institute, Massachusetts General Hospital;and a Professor of Psychiatry, Harvard Medical School.

A Cross-Sectional Analysis of Barriers Associated With Non-Attendance at a Urology Telehealth Clinic in a Safety-Net Hospital

To analyze the factors associated with non-attendance at a urology telehealth clinic in a large urban safety-net hospital after institutional-mandated transition to telehealth due to COVID-19. We identified all encounters scheduled for telehealth after March 17, 2020 and in the subsequent 8 weeks. Logistic regression was used to identify factors associated with attendance. In total there were 322 telehealth encounters, 228 (70.8%) of which were attended and 94 (29.2%) that were not attended. Racial/ethnic minorities accounted for 175 (77.0%) of attended and 73 (76.7%) of non-attended encounters. On multivariable regression, single/divorced/widowed (odds ratio [OR] 2.36, 95% confidence interval [CI] 1.26-4.43), current substance use disorder (OR 5.33, 95% CI 2.04-13.98), and being scheduled for a new patient appointment (OR 1.81, 95% CI 1.04-3.13) were associated with higher odds of not attending a telehealth encounter. Race/ethnicity, primary language, and country of birth were not associated with odds of attendance. Our findings identify several social factors (social support, substance use) associated with non-attendance at outpatient telehealth urology encounters at an urban safety-net hospital during the early stages of the COVID-19 pandemic. These barriers may have a greater impact specifically within a safety-net healthcare system and will inform equitable provision of urology telehealth programs in the future FUNDING: Goldberg-Benioff Endowed Professorship in Cancer Biology. The sponsors had no involvement with this study.

Implicating Gene and Cell Networks Responsible for Differential COVID-19 Host Responses via an Interactive Single Cell Web Portal

Numerous studies have provided single-cell transcriptome profiles of host responses to SARS-CoV-2 infection. Critically lacking however is a reusable datamine to allow users to compare and explore these data for insight, inference, and hypothesis generation. To accomplish this, we harmonized datasets from blood, bronchoalveolar lavage and tissue samples from COVID-19 and other control conditions and derived a compendium of gene signature modules per cell type, subtype, clinical condition and compartment. We demonstrate approaches for exploring and evaluating their significance via a new interactive web portal (ToppCell). As examples, we develop three hypotheses: (1) a multicellular signaling cascade among alternatively differentiated monocyte-derived macrophages whose tasks include T cell recruitment and activation; (2) novel platelet subtypes with drastically modulated expression of genes responsible for adhesion, coagulation and thrombosis; (3) a multilineage cell activator network able to drive extrafollicular B maturation via an ensemble of genes extensively associated with risk for developing autoimmunityFunding Information: Funding for this study was provided by LungMap (U24 and HL148865), Digestive Health Center (P30, DK078392) and Harold C. Schott Foundation funding of the Harold C. Schott Endowed Chair, UC College of Medicine.Declaration of Interests: The authors declare no competing interest.

Quality Improvement Studies in Pediatric Critical Care Medicine.

1 Division of Neonatology, Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH 2 John F. Wolfe Endowed Chair in Medical Leadership and Pediatric Quality and Safety; Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH The authors have disclosed that they do not have any potential conflicts of interest. For information regarding this article, E-mail: [email protected]

Abstract 2547: DNA damage level correlates with grade of cervical dysplasia: a potential biomarker to assess cervical cancer risk

Abstract Background: In 2018, cervical cancer (CC) accounted for 311,000 deaths worldwide. Nearly all CC are linked to human papillomavirus (HPV) infection. HPV infection is nearly ubiquitous, but persistent infection can lead to dysplasia and ultimately cancer. Cervical dysplasia is classified into low (CIN1), moderate (CIN2), and high (CIN3) cervical intraepithelial neoplasia. CIN2 and CIN3 are considered premalignant lesions, with about 5-12% progressing to CC. However, it is unclear which of these high-risk CIN2/3 patients will go on to develop CC. Chronic HPV infection increases DNA damage and reduces DNA repair. Using a novel, highly sensitive, DNA damage detection assay (q-PADDA) developed in our lab, we have recently shown that nuclear DNA (nDNA) damage is a potential tool to predict oropharyngeal cancer risk, another HPV infection associated malignancy. Herein, we hypothesized that nDNA damage could also be used as a tool to screen for high CC risk. Aims: (1) To measure the amount of nDNA damage in cervical samples with distinct pathologies. (2) To determine whether the number of DNA lesions correlates with the grade of cervical dysplasia. Methods: A total of 105 participants were enrolled in the study. Cervical samples were collected using a cytobrush during pelvic examination. Total genomic DNA was extracted, and nDNA damage was quantified using q-PADDA. Demographic, clinicopathologic, and risk factor data were collected from detailed questionnaires and medical charts. Data were subjected to ANOVA and regression analysis using SAS software. Results: Histopathological analysis revealed that 33 samples had no dysplasia (CIN0), 30 samples were CIN1, 37 samples were CIN2/3, and five samples were CC. DNA damage analysis has been completed in 26 samples. We observed that CIN1 cases had a 2-fold (p<0.05), and CIN2/3 cases had a three-fold (p≤0.02) increase in the number of nDNA lesions when compared to CIN0. No significant correlation was observed between age, race, smoking and alcohol status and final pathology per regression analysis. Conclusion: Our preliminary analysis reveals that the amount of DNA damage is the lowest in patients without cervical dysplasia and increases progressively with the grade of dysplasia and corresponding CC risk. This promising data supports the use of DNA damage as biomarker of cervical cancer risk. The remainder of this data will be analyzed, but more extensive population studies are warranted to fully assess the potential of this approach to predict CC risk. Grant support: This work was supported by OSCTR/NIH IDeA Program and The Peggy and Charles Stephenson Cancer Center. Dr. Queimado holds a PHF Endowed Chair in Otorhinolaryngology. Citation Format: Balaji Sadhasivam, Camille C. Jackson, Katie M. Smith, Tristan Coles, Isha Jhingan, Rebekah Stewart, Elizabeth H. Hahn, Sarah E. Johnston, Daniel Y. Zhao, Vengatesh Ganapathy, Lurdes Queimado. DNA damage level correlates with grade of cervical dysplasia: a potential biomarker to assess cervical cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2547.

Abstract 2075: DNA damage on HPRT as a biomarker of susceptibility to tobacco-induced cancer

Abstract Background: The prevention of cancer and the development of more effective strategies to detect cancer precursor lesions and early-stage cancers remain critical goals. It has been estimated that 50% - 60% of cancers could be prevented if known strategies were optimally used. Cancer risk is not uniform, but varies based on age, genetic susceptibility, exposures, existence of preneoplastic conditions across the population. The DNA is constantly damaged by exogenous and endogenous sources. DNA repair mechanisms maintain the integrity of the genome. DNA damage has emerged as a major culprit in tumorigenesis and progression. There are numerous strategies with inherent advantages and disadvantages that may be used for the evaluation of DNA damage and repair. We have developed a novel and highly sensitive primer-anchored DNA damage detection assay (PADDA) to map and quantify DNA damage in p53, the most frequently mutated gene in human cancer. Here, we have extended this assay to HPRT (hypoxanthine-guanine phosphoribosyltransferase), the gene most frequently analyzed in DNA damage studies. Aim: (1) To quantify the amount of DNA damage in HPRT in peripheral blood cells of never-smokers, smokers, and secondhand smokers. (2) To determine whether cancer patients have higher levels of DNA damage in HPRT than non-cancer patients. Methods: The assay, PADDA was used on a high-throughput setting to quantify DNA damage (q-PADDA) on the HPRT gene. DNA was extracted and damage was quantified by q-PADDA in peripheral blood cells collected from non-cancer patients [never-smokers (n=28), tobacco smokers (n=25), secondhand smokers (n=18)], and cancer patients (n=66). Pairwise comparisons in DNA damage among the diverse groups were performed using the Tukey's adjustment in a one-way ANOVA model. Linear regression models were also used to test difference in DNA damage between cancer and non-cancer groups. Results: Never-smokers, tobacco smokers, and secondhand smokers had similar age distribution. In non-cancer patients, the amount of DNA damage in the HPRT gene in smokers was significantly higher than in non-smokers (p=0.01). Secondhand smokers also showed higher levels of DNA damage than never-smokers but this difference did not reach significance. Among cancer patients (n=64), smokers (n=29) showed significantly higher levels of DNA damage (p=0.03) than non-smokers (n=16). Conclusion: Our preliminary data document PADDA's ability to quantify DNA damage on HPRT gene. Damage was significantly higher in smokers than never-smokers, both in cancer and non-cancer patients. Application of this assay to a larger population sample has a major potential to establish biomarkers of susceptibility to tobacco-induced cancer, which can guide preventive and diagnostic strategies. Funding: This work was supported by the NIH, NCI (1R33 CA202898-01, LQ). Dr. Queimado holds a Presbyterian Health Foundation Endowed Chair in Otorhinolaryngology. Citation Format: Mayilvanan Chinnaiyan, Daniel Brobst, Balaji Sadhasivam, Vengatesh Ganapathy, Sarah E. Johnston, Daniel Zhao, Greg A. Krempl, Lurdes Queimado. DNA damage on HPRT as a biomarker of susceptibility to tobacco-induced cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2075.

Abstract 2021: Differential expression of antioxidant and detoxifying enzymes induced by e-cigarette aerosol

Abstract Background: Last decade, there has been an increasing interest in the use of electronic cigarette (e-cig) among the youths. E-cigs are promoted as a safer alternative to tobacco cigarettes, but the long term health effects of e-cigs are unknown. E-cig aerosols contain harmful and potentially harmful substances, i.e., nicotine, ultrafine particles, flavoring agents, carbonyl compound, heavy metals, and carcinogens. In addition to containing reactive oxygen species (ROS), e-cig aerosols can also increase the cellular ROS production potentially leading to further alterations in the antioxidant system and its regulators. A recent in-vitro study from our laboratory showed that e-cigs aerosols can suppress the cellular antioxidant defenses and induced oxidative DNA damage in human epithelial cells. The effects of e-cig aerosols on antioxidant and detoxifying enzymes and its regulators are unknown. Aims: To investigate whether exposure to EC aerosol extracts alters the expression of antioxidant and detoxifying enzymes in human epithelial cells. Methods: Human oral epithelial cancer (UM-SCC-1) and non-cancer (POE9n) cell lines were exposed every other day for 2 weeks to e-cig aerosol. E-cig aerosols were prepared from two distinct e-cig brands (18 mg/ml of nicotine; tobacco flavor). Standard tobacco extracts (mainstream smoke, MS) were used as positive control. Gene and protein expression were quantified by RT-PCR and Western blotting respectively. Data were analyzed by Student's t-test and ANOVA. Results: Exposure to e-cig aerosol, but not to MS smoke, led to a decrease in NRF2 and SOD2 mRNA expression in both cell lines. A significant decrease in protein expression was also observed for NRF2 protein after exposure to e-cig aerosol. A significant increase in CYP1B1 was observed after exposure to e-cig aerosol and MS smoke. Conclusion: E-cig aerosol exposure decreases the expression of NRF2 a major regulator of the antioxidant response. This might put the cell under additional oxidative stress which can have major biological implications. E-cig aerosol exposure increases the expression of CYP1B1, a protein with a key role in the bioactivation of tobacco pro-carcinogens and the regulation of the redox homeostasis. Overall, our study suggests that e-cig aerosol not only carries high levels of ROS, but also alters the cellular detoxification and antioxidant system leading to a higher oxidative stress status that would be anticipated. Grant support: This work was supported by the National Institutes of Health, National Cancer Institute (R01CA242168). Dr. Queimado holds a Presbyterian Health Foundation Endowed Chair in Otorhinolaryngology, Oklahoma Tobacco Research Center (LQ). Citation Format: Vengatesh Ganapathy, Jimmy Manyanga, Lurdes Queimado. Differential expression of antioxidant and detoxifying enzymes induced by e-cigarette aerosol [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2021.

Prevalence of Gluten Contamination in Certified and Non-Certified Foods Labelled “Gluten-Free”

Abstract Objectives Gluten is a common protein found in wheat, rye, and barely, and can sometimes be found in products that do not contain these grains. Gluten contamination in naturally gluten-free foods, products processed to remove gluten, and foods made with non-gluten derivatives is of concern for those suffering from an intolerance to gluten, such as Celiac disease. For these individuals, knowing whether or not food products advertised as “gluten-free” are truly so is necessary for their health and safety. The current study was designed to determine the reliability of “gluten-free” food labels in the consumer marketplace. Methods Samples of “gluten-free” foods were collected from a variety of locations, including grocery stores, health-food stores, and other non-grocery retailers. A total of 243 samples were analyzed using a Nima Gluten Sensor (antibody-based colorimetric assay) to determine if gluten content was < 20 ppm, the maximum allowed by US law for a product labeled “gluten-free”. Results Of the samples tested, 98 were certified as “gluten-free” (<10 ppm) by the Gluten-Free Certification Organization (GFCO); only 13 of these (13.3% of samples) were found to exceed 20 ppm of gluten. By comparison, 145 samples were labeled “gluten-free” on the packaging but did not contain GFCO or other recognized certification; of these, 42 (29.0%) were found to actually contain more gluten than allowed by law. Samples obtained from grocery stores (n = 161) and health-food stores (n = 29) had relatively few positive results (14.3% and 13.8% respectively), whereas samples obtained from stores whose primary function is not to sell food (n = 53) were much more likely to exceed the federal limit on gluten (43.4% of samples tested). Conclusions While results reveal that “certified gluten-free” products (GFCO or other organizations) should be more trusted by consumers in their claim of being “gluten-free”, contamination still poses some risk to those who are intolerant of gluten, and that risk is increased when certification is absent. Funding Sources Funding for this study came from the Robert M. Geist Endowed Chair in the Biological Sciences at Capital University.

Plasma Volume Is an Important Determinant in Assessing Metabolic and Iron Biomarkers in Young Women

Abstract Objectives Plasma volume (PV) variations among individuals can affect the concentration of blood biomarkers but this is not often evaluated in assessing nutritional status. We aimed to assess the association between estimated PV, metabolic and iron biomarkers in young obese and normal weight women. Methods Healthy women aged 18–30 y were recruited for the study (n = 47: 25 obese and 22 normal weight). Fasting venous blood samples were obtained to measure serum lipids, comprehensive metabolic panel, iron biomarkers (serum iron, total iron binding capacity, transferrin saturation (%TS), hemoglobin, ferritin and, hepcidin). PV was estimated using Kaplan-Hakim formula: PV = (1-hematocrit) × [a + (b × weight in kg)] where adjustment factors were a = 864, and b = 47.9. Associations between PV and other biomarkers were assessed using Pearson's correlation. Results As expected, PV was higher in obese (3482 (545) mL) than normal weight women (2268 (250) mL). When all subjects were combined PV was negatively correlated with HDL (r = −0.49, P = 0.001), creatinine (r = −0.48, P = 0.001), sodium (r = −0.31, P = 0.034), calcium (r = −0.30, P = 0.044), albumin (r = −0.46, P = 0.001), serum iron (r = −0.34, P = 0.022), and %TS (r = −0.31, P = 0.036) but positively correlated with triglycerides (r = 0.40, P = 0.005), cholesterol/HDLC ratio(r = 0.55, P < 0.001). In normal weight women, PV was not correlated with any of these biomarkers. However, in obese women, there was a strong correlation of PV with creatinine (r = −0.61, P = 0.001), calcium (r = −0.50, P = 0.012), and albumin (r = −0.43, P = 0.030). Conclusions Our results suggest that differences in PV may account for some variations in serum lipids, creatinine, sodium, calcium, albumin, and iron biomarker concentrations in women. This implies that different cutoffs may be needed for defining deficiencies in obesity after correcting for plasma volume. Funding Sources Doris A. Adams Endowed Chair funds at Iowa State University.

Factors associated with endowed chair allocation in medical oncology divisions and departments in the United States.

11044 Background: Despite an increasing number of female physicians in the workforce, a gender disparity remains in many leadership roles in medicine. Endowed chairs can provide a multitude of research and career opportunities; thus, they are coveted positions in academic medicine. We examined factors associated with holding endowed chairs in oncology across the US, with a focus on whether a gender difference existed, as has been demonstrated in top internal medicine departments more generally. Methods: In 2019, we identified 95 academic oncology divisions/departments in the US, using the Oncology Division Chiefs & Department Chairs listing in the American Society of Clinical Oncology (ASCO) myConnection forum to define the institutions included. We requested a list of full professors and endowed chairs in those divisions/departments, relying on public data on websites when an institution did not respond. Using public data (e.g., institutional websites, NIH reporter, Scopus, state licensing boards), we collected information on gender, degree, total NIH funding as PIs, H-indices, publication and citation numbers, and graduation year for these individuals. We then created a multivariable logistic regression model to examine if, after controlling for other variables, gender was independently associated with an increased likelihood of holding an endowed chair. Results: One thousand thirty-three oncology full professors were identified, 290 (25.6%) of whom held endowed chairs. Overall, and in an adjusted model, greater research productivity (as measured through publications, citations, and h-index) and greater levels of NIH funding were significantly associated with having an endowed chair. Gender was not significantly associated with endowed chair status (21.9% [95% CI:17.2-27.3] of females and 26.8% [23.8-29.9] for males held endowed chairs; p = 0.11) on bivariable analysis, nor was it significant in the adjusted multivariable model (p = 0.50). Power to detect the observed difference given the total number of professors and their gender distribution was found to be ̃53%, suggesting a 47% chance of failing to reject the null hypothesis of equal gender distributions in endowed chairs when the observed difference is as large as estimated. Conclusions: Among oncology full professors, gender was not significantly associated with endowed chair status, although the number of professors in this field is too small to definitively rule out a modest gender difference. This finding contrasts with prior work that revealed a more substantial difference by gender that remained significant after controlling for other factors in a study, including all divisions in the Departments of Internal Medicine at top medical institutions. Further work is necessary to understand what specialty-specific and institutional cultural factors may help mitigate challenges in the pursuit of equity, diversity, and inclusion.

Roxana Mehran: driving force in women's cardiovascular health

Roxana Mehran's remarkable career as an interventional cardiologist and clinical trialist has been wide-ranging. She is the Mount Sinai Endowed Chair of Cardiovascular Research and Outcomes, and Professor of Medicine, Cardiology, and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA, and is the lead Commissioner of the Lancet women and cardiovascular disease Commission. “There has been an alarming stagnation in death rates due to cardiovascular disease among women in the past decade. This Commission will set out what needs to be done, with clear actions and metrics that we can track and report back on in 2030”, she says. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030Cardiovascular disease is the leading cause of death in women. Decades of grassroots campaigns have helped to raise awareness about the impact of cardiovascular disease in women, and positive changes affecting women and their health have gained momentum. Despite these efforts, there has been stagnation in the overall reduction of cardiovascular disease burden for women in the past decade. Cardiovascular disease in women remains understudied, under-recognised, underdiagnosed, and undertreated. This Commission summarises existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. Full-Text PDF

In Memoriam

In Memoriam

In Memoriam: Bernardine Mays Lacey

Figure: Photo courtesy of Sandra B. Lewenson.Bernardine Mays Lacey, a trailblazing nursing leader, advocate, researcher, educator, and mentor, died on March 26 at age 88. During her 60-year career, Lacey held several notable positions, including founding dean and professor at Western Michigan University's School of Nursing in Kalamazoo and special assistant to Marian Wright Edelman at the Children's Defense Fund in Washington, DC. She helped found Federal City Shelter in Washington, DC—one of the first nurse-managed health clinics for the homeless. She was proud of her accomplishments, especially those that supported others in nursing and health care. Lacey was recognized by the nursing community for her many achievements. In 1990 she was inducted as a fellow of the American Academy of Nursing, which named her a Living Legend in 2014. Western Michigan University established an endowed chair in community health nursing in her honor in 1998. Lacey received the R. Louise McManus Medal from the Nursing Education Alumni Association of Teachers College, Columbia University, and the American Nurses Association's Pearl McIver Public Health Nurse Award. She was also awarded more than $2 million in grants for her work, including her efforts to improve health care for residents of homeless shelters and to support diverse students in nursing education. Lacey was born in 1932 in Vicksburg, Mississippi. During much of her early childhood and adult years, racial segregation existed as an accepted norm. She was one of the few Black students to be admitted to the Gilfoy School of Nursing at Mississippi Baptist Hospital in Jackson, which she attended from 1959 to 1962. Lacey acknowledged in a recent oral history interview the disparaging harshness she experienced (see ‘“You Don't Have Any Business Being This Good’: An Oral History Interview with Bernardine Lacey,” Special Feature, August 2020). She described, for instance, how Black nursing students were forced to sit in the back of the class and often had separate clinical experiences from White students. Lacey openly shared her experiences with racism and discussed how her resiliency and the support of her family, friends, and mentors helped her move beyond the limits imposed by racist attitudes and practices. Lacey earned a bachelor's degree in nursing from Georgetown University, a master's degree in sociology from Howard University, and a doctoral degree from Teachers College, Columbia University. Her education, experience, and wisdom enriched the lives of many, including her students and colleagues. Always a health care advocate, Lacey used her story to spark conversations about diversity and inclusion. She had a sincerity that nurtured many of us in nursing today, and she frequently reminded us of the need to appreciate one's family and one's work. She was tireless—forever involved in the nursing profession and keeping her finger on its pulse. She will be sorely missed.—Sandra B. Lewenson, EdD, RN, FAAN, and Ashley Graham-Perel, MEd, RN, NPD-BC, CNE

Effects of disease and dexamethasone on human cartilage breakdown kinetics

Effects of disease and dexamethasone on human cartilage breakdown kinetics

Charting your path to endowed or distinguished: A guide for mid‐career faculty members

AbstractTwo of the most prestigious, yet elusive, titles that professors in higher education can earn are the designations of distinguished professor and endowed chair. These named positions often come with benefits such as salary enhancements, resources for research and teaching, and favorable adjustments of time allocation within a faculty member's position description and job responsibilities. Often, though, mid‐career faculty know little about how they can intentionally pursue these positions. This chapter provides tangible tools to assist mid‐career faculty in understanding what endowed and distinguished positions are and how to best prepare for and pursue such positions. It also provides recommendations for how institutions can be intentional in supporting such professorial advancements.

William R. Hiatt

Free AccessWilliam R. HiattJune 1, 1950–December 8, 2020Published Online:February 28, 2021https://doi.org/10.1024/0301-1526/a000936PDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit SectionsMoreWe are deeply saddened to announce that Dr. William R. Hiatt passed away on December 8, 2020. Dr. Hiatt dedicated his life to improving the care of patients. His death represents a profound loss of one of the pillars of Vascular Medicine and cardiovascular research as well as a dedicated mentor to many of us. He dedicated his knowledge to all of us, irrespective if cardiologist, angiologist, cardiac or vascular surgeon, or pure researcher.William R. Hiatt was born 1950 in Colorado. He graduated from the University of Colorado School of Medicine and after his Internal Medicine residency in Boston and he completed his fellowship in Vascular Medicine at the University of Colorado. He became Professor of Medicine at University of Colorado where he held the Novartis Foundation Endowed Chair in Cardiovascular Research.Dr Hiatt dedicated his career to the care of patients with vascular disease, particularly peripheral artery disease. He was a Past President of the Society of Vascular Medicine. In addition, he served as Chair of the American Heart Association’s Council on Peripheral Vascular Disease. He was also a co-editor for the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC) guidelines. During his career he received numerous awards for his work, including the designation as a Master of the Society for Vascular Medicine and the Distinguished Scientist and Clinical Research Scientist Awards from the American Heart Association.He realized that he could have the greatest impact on patient outcomes by not only caring for individuals in clinic but also through leading cardiovascular research. He served as a member on several FDA Advisory Committees and the Chair of the US FDA Cardiovascular and Renal Division Advisory Committee. He was recognized with the FDA Advisory Committee Service Award in 2008.He published over 280 manuscripts, including landmark publications evaluating optimal therapies in peripheral artery disease and authored over 60 book chapters. He served as a teacher and mentor for numerous physician scientists and provided care to countless patients with complex cardiovascular disease. Will Hiatt dedicated extensive effort to physiologic studies and became a master of measuring functional outcomes. His mission to improve outcomes in peripheral artery disease spanned early and late phase trials, small and big studies, population studies, and registration pathway trials. His work led to the collaborative leadership of the EUCLID trial [1], the largest dedicated PAD medical therapy trial. One of his greatest and his latest achievement was the leadership and execution of VOYAGER PAD [2]. This trial had a major impact on reducing major cardiac and limb events in patients suffering from peripheral artery disease requiring lower extremity revascularization, and he gratefully was just able to finish this landmark trial. His legacy of dedication to the care of patients with peripheral artery disease has helped to transform research in this area and holds promise to improve outcomes in this high-risk population.Will was not just a remarkable physician and scientist. He was a remarkable human being. He was uncommonly grounded, humble, grateful and generous. Will didn′t care for profession, origin and community. Everyone, independent of her/his profession, was heartedly welcomed by him, and he truly was a great mentor to all of us, having had the honor of working with him and share his thoughts. For many of us, he was a true friend. Will had a sense of higher mission – beyond our daily tasks. His high sense for ethical attitude was summarized in the Code of the West [3]:Live each day with courageTake pride in your workAlways finish what you startDo what has to be doneBe tough, but fairWhen you make a promise, keep itRide for the brandTalk less and say moreRemember that some things aren’t for saleKnow where to draw the lineSebastian Debus, Rupert Bauersachs and Marc BonacaReferences1 Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32–40. Crossref Medline, Google Scholar2 Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004. Crossref Medline, Google Scholar3 Owen JP. Cowboy ethics. Ketchum, USA: Stoecklein Publishing; 2005. Google ScholarProf. Dr. Rupert Bauersachs, Director of the Department of Vascular Medicine – Angiology, Vascular Center, Klinikum Darmstadt GmbH, Grafenstraße 9, 64283 Darmstadt, Germany, E-mail bauersachs@em.uni-frankfurt.deFiguresReferencesRelatedDetails Volume 50Issue 2February 2021ISSN: 0301-1526eISSN: 1664-2872 InformationVasa (2021), 50, pp. 157-157 https://doi.org/10.1024/0301-1526/a000936.© 2021Hogrefe AGPDF download

Editorial introductions.

Editorial introductions.

About the Master.

See related article on p. 130Doug Green is the Peter C. Doherty Endowed Chair of Immunology at St. Jude Children's Research Hospital (Memphis, TN). Prior to this, he was Head of the Division of Cellular Immunology at the La Jolla Institute for Allergy and Immunology. Doug received his Bsc (1977) and PhD (1981) from Yale University (New Haven, CT), followed by postdoctoral work in experimental surgery and marine ecology, also at Yale. He joined the faculty at the University of Alberta in Edmonton in 1985, where he attained the rank of Associate Professor. He moved to what is now the La Jolla Institute of Immunology in 1990 and to St. Jude in 2005. His research has focused on the process of active cell death and cell survival, extending from the role of cell death in the regulation of cancer and immune responses in the whole organism to the fundamental molecular events directing the death of the cell. More recently, he discovered the process of LC3-associated phagocytosis, which links the autophagy pathway to phagosome maturation. Other areas of intense interest include regulated necrosis and metabolic reprogramming during asymmetric division in T lymphocytes. He has published over 600 papers, chapters, commentaries, and books and is an ISI “highly cited” investigator. In 2017, he was awarded the Jürg Tschopp Prize for research on cell death. He is an honorary fellow of Trinity College, Dublin, an honorary Einstein Professor in China, and a foreign fellow of the Royal Society of Canada and received an honorary PhD from Tor Vergata University of Rome. His most recent book is “Apoptosis and Other Cell Death Mechanisms: Means to an End,” published in 2018 by Cold Spring Harbor Laboratory Press. His wife, Rona Mogil (PhD, Yale, 1985), and daughter, Maggie Green (BA, Yale, 2014), are much smarter than he is and display great patience in putting up with him.

Continued Growth and Advances in Ambulatory Anesthesiology

Article| February 2021 Continued Growth and Advances in Ambulatory Anesthesiology Catlin Nalley Catlin Nalley Search for other works by this author on: This Site PubMed Google Scholar ASA Monitor February 2021, Vol. 85, 27. https://doi.org/10.1097/01.ASM.0000733860.08295.6c Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Twitter LinkedIn Cite Icon Cite Get Permissions Search Site Citation Catlin Nalley; Continued Growth and Advances in Ambulatory Anesthesiology. ASA Monitor 2021; 85:27 doi: https://doi.org/10.1097/01.ASM.0000733860.08295.6c Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsASA Monitor Search Advanced Search Topics: ambulatory care facilities, anesthesia, ambulatory, pain management, surgical procedures, operative Decades ago, sending a patient home the same day he or she underwent surgery was unheard of. However, ongoing advancements in surgical practices as well as improvements in postoperative care have made this the norm. Since it was first proposed in the mid-19th century, ambulatory anesthesia has become an integral component of the surgical experience. The discovery of more effective short-acting anesthetic drugs as well as a tailored approach to care has made it possible for the specialty to support a growing demand for safe and efficient ambulatory procedures. During an interview with the ASA Monitor, Tong Joo (TJ) Gan, MD, MHS, FRCA, MBA, Professor and Distinguished Endowed Chair, Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, shared his perspective on the growth of ambulatory anesthesiology and what the future may hold. ASA Monitor: How has the field of ambulatory anesthesiology evolved? Dr. Gan: Ambulatory anesthesia... You do not currently have access to this content.

Celebrating the 75th birthday of Professor Wladek Minor, one of the most accomplished Polish-American structural biologists.

This paper describes the scientific career and accomplishments of Professor Wladek Minor, who holds an endowed chair at the University of Virginia in Charlottesville, USA. Prof. Minor is a coauthor of data processing software used by macromolecular crystallographers world-wide, as well as of structural biology servers and of a repository for raw diffraction data. He made major contributions to the validation of biostructural data, with special focus on drug design targets and reproducibility in biomedical research. He is among the most highly cited molecular biologists ever.